News

GSK and S&P 500 Performance During 2007-08 Crisis. GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...
GSK may not be the ideal income stock for the moment The company's return on investment YTD stands at a paltry 2.50%, which is significantly below the sector average of 9.45%.
GSK (GSK) closed at $37.56 in the latest trading session, marking a +0.59% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 0.43%.
GSK is demonstrating strong operating performance and expects record sales for Shingrix this year. See why I rate GSK stock a strong buy. ... the stock has seen an 18% decline over the past ...
In the latest market close, GSK (GSK) reached $41.90, with a -1.04% movement compared to the previous day. The stock fell short of the S&P 500, which registered a gain of 0.52% for the day. Elsewhere, ...
The main aim of stock picking is to find the market-beating stocks. But the main game is to find enough winners to more than offset the losers So we wouldn't blame long term GSK plc (LON:GSK) ...
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance. 1w. GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American ... driven by strong performance across all ...
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...